Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
01 août 2023 07h05 HE | uniQure Inc.
~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington’s disease showing preservation of function compared to baseline and clinical benefits...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
26 juin 2023 07h11 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Change in Total Motor Score
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
21 juin 2023 07h05 HE | uniQure Inc.
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural...
Logo-uniQure-MS-Word_Orange.jpg
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
20 juin 2023 07h05 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 juin 2023 07h05 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 16, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
15 mai 2023 07h05 HE | uniQure Inc.
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
09 mai 2023 07h05 HE | uniQure Inc.
~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
02 mai 2023 16h40 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2023 07h05 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 mars 2023 07h05 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...